<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03234361</url>
  </required_header>
  <id_info>
    <org_study_id>STU 012017-052</org_study_id>
    <nct_id>NCT03234361</nct_id>
  </id_info>
  <brief_title>Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate</brief_title>
  <official_title>Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increasing number of studies have indicated that most fast food and common grocery items,&#xD;
      contain large amount of inorganic phosphate-based food additives , which are highly&#xD;
      absorbable. The long-term cardiovascular consequences of a high phosphate diet are unknown&#xD;
      but the existing database implicates phosphate excess as an independent risk factor for&#xD;
      cardiovascular events in individuals with and without chronic kidney diseases (CKD). High&#xD;
      phosphate consumption clearly induces BP elevation in rats with normal kidneys. However, the&#xD;
      mechanisms underlying phosphate-induced hypertension and the relevance of these rodent&#xD;
      studies to human hypertension have not been determined. We seek to investigate the role of&#xD;
      high phosphate diet in human hypertension and assess the effect of high phosphate diet on&#xD;
      muscle sympathetic nerve activity and the exercise pressor reflex.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Animal studies suggest that high phosphate diet raises blood pressure but the mechanism&#xD;
      underlying this phenomenon is not known. To study the effect of high phosphorus diet on blood&#xD;
      pressure in humans, we will perform randomized crossover studies in stage 1 prehypertensive&#xD;
      subjects. To ensure stable Pi intake prior to randomization, Pi consumption will be estimated&#xD;
      by food recall during a run-in and washout phase for 2 consecutive days, using the Automated&#xD;
      Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool&#xD;
      (https://epi.grants.cancer.gov/asa24/). After the run-in period, all subjects will be&#xD;
      maintained on a low Pi diet (700 mg/d) and a low Na diet of approximately 1,930 mg/d&#xD;
      throughout the study for 8 weeks. Subjects will also be randomized to receive Sodium&#xD;
      Phosphate 2 capsules daily (containing a total of 500 mg of Pi, 372mg of sodium) for 4 weeks&#xD;
      during the high Pi phase (total Pi intake 1,200 mg/d) vs 2 capsules of Sodium Chloride (NaCl,&#xD;
      containing a total of 372mg of sodium) to match Na content to Sodium Phosphate without extra&#xD;
      Pi daily for 4 weeks during the low Pi phase (total Pi intake = 700 mg/d).&#xD;
&#xD;
      The total Na intake during the entire study will be at recommended level of 2,300 mg/d.&#xD;
      Investigational drug service at UT Southwestern will dispense Sodium Phosphate vs. NaCl&#xD;
      tablets tablets and the study subjects will be blinded to the type of supplement they&#xD;
      receive.&#xD;
&#xD;
      During the periods of high and low Pi phases, we will monitor 24-hr UPiV to ensure adherence.&#xD;
      Since approximately 70% of ingested Pi is absorbed and excreted in the urine, we expect 24-hr&#xD;
      UPiV excretion to be approximately 840 mg during the high Pi phase and 490 mg during the low&#xD;
      Pi phase. If 24-hr UPiV is &lt; 800 mg during the high Pi diet or &gt; 500 mg during the low Pi&#xD;
      diet, the research dietitian will provide additional counseling to improve adherence to the&#xD;
      menu plan. If needed, the research diet will be altered to be more compatible with subject&#xD;
      preference. 24-hr UPiV will be reassessed within 1 week in these individuals. If the levels&#xD;
      remain below goal, subjects will be excluded from the study.&#xD;
&#xD;
      24-hr urinary Pi, Na, K, Cr, and Ca excretion will be assessed after weeks 2 and 4 of the low&#xD;
      and high Pi phases. Serum electrolytes and Pi will be monitored every 2 weeks. Serum FGF23,&#xD;
      PTH, and soluble Klotho levels and 24-h ambulatory BP will be obtained after 4 weeks on the&#xD;
      study diet. Then, on a separate day, we will assess muscle SNA and BP at rest and during&#xD;
      rhythmic handgrip of 30% and 45% each for 3 minutes. Additionally, we will test the role of&#xD;
      dietary Pi on the response to isometric exercise by assessing SNA and BP during static&#xD;
      handgrip at 30% MVC for 2 minutes followed by post exercise circulatory arrest (PECA). The&#xD;
      latter maneuver will maximally activate the metaboreflex. Each exercise intervention will be&#xD;
      separated by at least 30 minutes. The order of exercise intervention will be randomized.&#xD;
      Subsequently, subjects will stop the first study supplement and undergo washout for 2 weeks.&#xD;
      After 2 weeks of washout, they will receive the 2nd study supplement. Measurement of 24-h&#xD;
      ambulatory BP, SNA at rest and during handgrip exercise will be repeated in the same fashion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Blood Pressure measured by Ambulatory Blood Pressure Monitor.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Blood pressure will be measured through an ambulatory blood pressure monitoring device by Space Labs # 90217, worn by each participant after completing each phase, This will suggest if participant's blood pressure increased during high phosphorus phase as compared to low phosphorus phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle Sympathetic Nerve Activity (MSNA)</measure>
    <time_frame>4 weeks after high phosphorus and 4 weeks after low phosphorus diet</time_frame>
    <description>MSNA will be measured during both diet phases using microelectrodes inserted in the peroneal nerve. This will assess the impact of phosphate intake on MSNA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>High Phosphate Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium phosphate with 500mg/day of phosphate for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Phosphate Phase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will be on a low Pi diet containing 700mg/day of phosphate and 2 capsules of sodium chloride for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Phosphate Phase</intervention_name>
    <description>2 capsules of sodium phosphate with 500mg/day of phosphate.</description>
    <arm_group_label>High Phosphate Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Low Phosphate Phase</intervention_name>
    <description>2 capsules of sodium chloride.</description>
    <arm_group_label>Low Phosphate Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: (answer must be yes to all to enter trial; check yes or no)&#xD;
&#xD;
        º ≥ 18 years of age&#xD;
&#xD;
        º Stage 1 Prehypertension (office BP 120-129/80-84 mmHg and normal ABPM &lt;130/80)&#xD;
&#xD;
        Exclusion Criteria: (answer must be no to all to enter trial)&#xD;
&#xD;
        º Diabetes mellitus or other systemic disease&#xD;
&#xD;
        º Cardiopulmonary disease&#xD;
&#xD;
        º Treatment with antihypertensive medications&#xD;
&#xD;
        º eGFR&lt; 60 ml/min/1.73m2&#xD;
&#xD;
        º Pregnancy&#xD;
&#xD;
        º Hypersensitivity to nitroprusside or phenylephrine&#xD;
&#xD;
        º Psychiatric illness&#xD;
&#xD;
        º H/o substance abuse or current smoker&#xD;
&#xD;
        º H/o malignancy&#xD;
&#xD;
        º Serum Phos &lt;2.4 mg/dL or &gt;4.5 mg/dL&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wapen Vongpatanasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT southwestern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Arbique</last_name>
    <phone>2146482968</phone>
    <email>Debbie.Arbique@UTSouthwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Arbique, RN</last_name>
      <phone>214-648-2968</phone>
      <email>debbie.arbique@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hamza Lodhi, MD</last_name>
      <phone>214-648-3188</phone>
      <email>hamza.lodhi@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <phone>214-648-2103</phone>
      <email>Wanpen.Vongpatanasin@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Wanpen Vongpatanasin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sullivan CM, Leon JB, Sehgal AR. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients. J Ren Nutr. 2007 Sep;17(5):350-4.</citation>
    <PMID>17720105</PMID>
  </reference>
  <reference>
    <citation>Benini O, D'Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. J Ren Nutr. 2011 Jul;21(4):303-8. doi: 10.1053/j.jrn.2010.06.021. Epub 2010 Nov 5.</citation>
    <PMID>21055967</PMID>
  </reference>
  <reference>
    <citation>Ketteler M, Wolf M, Hahn K, Ritz E. Phosphate: a novel cardiovascular risk factor. Eur Heart J. 2013 Apr;34(15):1099-101. doi: 10.1093/eurheartj/ehs247. Epub 2012 Oct 7.</citation>
    <PMID>23045267</PMID>
  </reference>
  <reference>
    <citation>Karp H, Ekholm P, Kemi V, Itkonen S, Hirvonen T, Närkki S, Lamberg-Allardt C. Differences among total and in vitro digestible phosphorus content of plant foods and beverages. J Ren Nutr. 2012 Jul;22(4):416-22. doi: 10.1053/j.jrn.2011.04.004. Epub 2011 Jul 13.</citation>
    <PMID>21741857</PMID>
  </reference>
  <reference>
    <citation>Suzuki Y, Mitsushima S, Kato A, Yamaguchi T, Ichihara S. High-phosphorus/zinc-free diet aggravates hypertension and cardiac dysfunction in a rat model of the metabolic syndrome. Cardiovasc Pathol. 2014 Jan-Feb;23(1):43-9. doi: 10.1016/j.carpath.2013.06.004. Epub 2013 Aug 8.</citation>
    <PMID>23932324</PMID>
  </reference>
  <reference>
    <citation>Scanni R, vonRotz M, Jehle S, Hulter HN, Krapf R. The human response to acute enteral and parenteral phosphate loads. J Am Soc Nephrol. 2014 Dec;25(12):2730-9. doi: 10.1681/ASN.2013101076. Epub 2014 May 22.</citation>
    <PMID>24854273</PMID>
  </reference>
  <reference>
    <citation>Hu MC, Shi M, Cho HJ, Adams-Huet B, Paek J, Hill K, Shelton J, Amaral AP, Faul C, Taniguchi M, Wolf M, Brand M, Takahashi M, Kuro-O M, Hill JA, Moe OW. Klotho and phosphate are modulators of pathologic uremic cardiac remodeling. J Am Soc Nephrol. 2015 Jun;26(6):1290-302. doi: 10.1681/ASN.2014050465. Epub 2014 Oct 17.</citation>
    <PMID>25326585</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2017</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Wanpen Vongpatanasin</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>High phosphorus diet</keyword>
  <keyword>FGF 23</keyword>
  <keyword>24 hour ambulatory blood pressure</keyword>
  <keyword>Muscle sympathetic nerve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

